Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (1176)	3/25/1999 5:05:00 PM
From: lrb	Respond to of 1826

I present these two guesses just to provoke a response from more knowledgeable posters: 1. This agreement costs MGI very little. Their sales force would be making the calls anyway, they just have more to talk about once they get there. 2. In addition to generating income from sales of Luxiq and Ridaura, it could help drive Salagen sales. My thinking is that with three products to talk about instead of just one, it will be easier to get customers to listen to them, so they will find more doors open to them. Does this make any sense? --lrb

To: Russian Bear who wrote (1176)	3/25/1999 7:09:00 PM
From: sim1	Read Replies (1) \| Respond to of 1826

"...The drug (Ridaura) is currently indicated for adults with active rheumatoid arthritis who are not responsive to, or are intolerant of, treatment with non-steroidal anti-inflammatory drugs (NSAIDs)." It would seem like the new Cox-2 inhibitors (Celebrex, Vioxx) might cut into or limit sales of Ridaura.